Metsera (MTSR) Proxy Filing summary

Executive summary

• The company is a clinical-stage biotech focused on next-generation injectable and oral NuSH analog peptides for obesity and related conditions, with a broad pipeline including GLP-1, amylin, GIP, and glucagon analogs, and proprietary MINT, HALO, and MOMENTUM platforms.

• The company completed its IPO in February 2025, raising $288.4 million in net proceeds, and had $530.9 million in cash and cash equivalents as of June 30, 2025, with an accumulated deficit of $402.4 million.

• The company has not generated revenue and expects to incur significant losses for the foreseeable future, with sufficient cash to fund operations into 2027.

Voting matters and shareholder proposals

• Shareholders are asked to vote on the adoption of the Merger Agreement with Pfizer and the approval of an Adjournment Proposal to solicit additional proxies if needed.

• The Board unanimously recommends voting FOR both proposals.

• Supporting stockholders representing over 37% of shares have entered into voting agreements to support the merger.

Board of directors and corporate governance

• The Board consists of experienced executives and independent directors, with standing Audit, Compensation, and Nominating and Corporate Governance Committees.

• The Board has adopted a Code of Business Conduct and Ethics and maintains standard governance practices.